Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BBNX NASDAQ:DCTH NASDAQ:KIDS NASDAQ:MBOT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBBNXBeta Bionics$10.60+4.8%$10.57$8.80▼$32.71$474.59M3.291.17 million shs356,644 shsDCTHDelcath Systems$11.43+1.7%$10.24$8.12▼$17.55$394.39M0.54434,335 shs243,473 shsKIDSOrthoPediatrics$18.44-0.4%$16.70$14.42▼$23.70$474.82M0.99163,660 shs105,519 shsMBOTMicrobot Medical$1.77+1.4%$2.32$1.60▼$4.67$118.56M1.061.88 million shs1.06 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBBNXBeta Bionics+7.55%+4.98%-21.69%-24.89%-36.17%DCTHDelcath Systems+3.50%-3.27%+3.22%+17.84%-37.51%KIDSOrthoPediatrics+1.48%+3.99%+11.11%+8.50%-19.18%MBOTMicrobot Medical+0.58%-19.82%-24.35%-19.07%-33.59%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBBNXBeta Bionics$10.60+4.8%$10.57$8.80▼$32.71$474.59M3.291.17 million shs356,644 shsDCTHDelcath Systems$11.43+1.7%$10.24$8.12▼$17.55$394.39M0.54434,335 shs243,473 shsKIDSOrthoPediatrics$18.44-0.4%$16.70$14.42▼$23.70$474.82M0.99163,660 shs105,519 shsMBOTMicrobot Medical$1.77+1.4%$2.32$1.60▼$4.67$118.56M1.061.88 million shs1.06 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBBNXBeta Bionics+7.55%+4.98%-21.69%-24.89%-36.17%DCTHDelcath Systems+3.50%-3.27%+3.22%+17.84%-37.51%KIDSOrthoPediatrics+1.48%+3.99%+11.11%+8.50%-19.18%MBOTMicrobot Medical+0.58%-19.82%-24.35%-19.07%-33.59%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBBNXBeta Bionics 2.67Moderate Buy$20.0088.75% UpsideDCTHDelcath Systems 2.43Hold$22.5096.94% UpsideKIDSOrthoPediatrics 2.82Moderate Buy$24.4432.60% UpsideMBOTMicrobot Medical 2.60Moderate Buy$7.50324.93% UpsideCurrent Analyst Ratings BreakdownLatest MBOT, KIDS, BBNX, and DCTH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/18/2026BBNXBeta Bionics Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$23.00 ➝ $11.005/11/2026DCTHDelcath Systems Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D) ➝ Sell (D+)5/11/2026DCTHDelcath Systems Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell5/1/2026KIDSOrthoPediatrics Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$17.005/1/2026KIDSOrthoPediatrics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$24.004/24/2026KIDSOrthoPediatrics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$25.004/22/2026BBNXBeta Bionics Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$25.00 ➝ $24.004/22/2026BBNXBeta Bionics Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$22.00 ➝ $20.004/21/2026BBNXBeta Bionics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/21/2026KIDSOrthoPediatrics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/15/2026BBNXBeta Bionics Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$25.00 ➝ $18.00(Data available from 5/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBBNXBeta Bionics$110.24M4.28N/AN/A$6.09 per share1.74DCTHDelcath Systems$85.23M4.63$0.06 per share207.56$3.26 per share3.50KIDSOrthoPediatrics$236.35M2.00$0.17 per share109.63$13.19 per share1.40MBOTMicrobot MedicalN/AN/AN/AN/A$1.10 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBBNXBeta Bionics-$73.20M-$1.51N/AN/AN/A-60.27%-23.00%-20.55%N/ADCTHDelcath Systems$2.70M$0.011,142.50N/AN/A0.62%0.51%0.46%8/5/2026 (Estimated)KIDSOrthoPediatrics-$39.65M-$1.68N/AN/AN/A-16.31%-7.01%-4.86%8/4/2026 (Estimated)MBOTMicrobot Medical-$13.14M-$0.26N/AN/AN/AN/A-21.84%-20.71%N/ALatest MBOT, KIDS, BBNX, and DCTH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026MBOTMicrobot Medical-$0.08-$0.05+$0.03-$0.05$0.30 million$0.11 million5/7/2026Q1 2026DCTHDelcath Systems-$0.0971-$0.03+$0.0671-$0.03$23.51 million$24.99 million4/30/2026Q1 2026KIDSOrthoPediatrics-$0.4552-$0.42+$0.0352-$0.45$58.29 million$59.36 million4/21/2026Q1 2026BBNXBeta Bionics-$0.53-$0.49+$0.04-$0.49N/A$27.63 million3/27/2026Q4 2025MBOTMicrobot Medical-$0.06-$0.04+$0.02-$0.04$0.11 millionN/A2/26/2026Q4 2025DCTHDelcath Systems-$0.06-$0.05+$0.01-$0.05$20.35 million$20.73 million2/26/2026Q4 2025KIDSOrthoPediatrics-$0.37-$0.26+$0.11-$0.43$61.27 million$61.61 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBBNXBeta BionicsN/AN/AN/AN/AN/ADCTHDelcath SystemsN/AN/AN/AN/AN/AKIDSOrthoPediatricsN/AN/AN/AN/AN/AMBOTMicrobot MedicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBBNXBeta BionicsN/A10.699.67DCTHDelcath SystemsN/A11.2410.33KIDSOrthoPediatrics0.295.212.37MBOTMicrobot Medical0.0122.5921.93Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBBNXBeta BionicsN/ADCTHDelcath Systems61.12%KIDSOrthoPediatrics69.05%MBOTMicrobot Medical16.30%Insider OwnershipCompanyInsider OwnershipBBNXBeta Bionics5.30%DCTHDelcath Systems19.36%KIDSOrthoPediatrics32.70%MBOTMicrobot Medical4.74%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBBNXBeta Bionics29444.56 million42.20 millionN/ADCTHDelcath Systems6034.52 million27.84 millionOptionableKIDSOrthoPediatrics20025.68 million17.29 millionOptionableMBOTMicrobot Medical2067.17 million63.98 millionOptionableMBOT, KIDS, BBNX, and DCTH HeadlinesRecent News About These CompaniesMicrobot Medical Inc. (NASDAQ:MBOT) Given Average Recommendation of "Moderate Buy" by BrokeragesMay 21 at 4:07 AM | americanbankingnews.comAfter Plunging 22.6% in 4 Weeks, Here's Why the Trend Might Reverse for Microbot Medical (MBOT)May 19 at 10:36 AM | zacks.comMicrobot Medical Inc. (MBOT) Shareholder/Analyst Call TranscriptMay 19 at 3:01 AM | seekingalpha.comMicrobot Medical (NASDAQ:MBOT) Upgraded by Wall Street Zen to "Sell" RatingMay 16, 2026 | americanbankingnews.comMicrobot Medical to Hold Analysts and Investors Conference Call to Review Recent Progress; Executive Team will be Joined by Current Users of the LIBERTY Endovascular Robotic ...May 15, 2026 | markets.businessinsider.comMicrobot Medical Inc. to Host Conference Call Addressing Misrepresentations from Unaffiliated Third-Party ArticleMay 15, 2026 | quiverquant.comQMicrobot Medical to Hold Analysts and Investors Conference Call to Review Recent Progress; Executive Team will be Joined by Current Users of the LIBERTY Endovascular Robotic System, Dr. Charles Briggs and Dr. Zachary BercuMay 15, 2026 | globenewswire.comMicrobot Medical Affirms Stability, Advances LIBERTY U.S. LaunchMay 14, 2026 | theglobeandmail.comMicrobot Medical stock drops after White Diamond short reportMay 14, 2026 | investing.comMicrobot Medical plunges amid results, short report from White Diamond ResearchMay 14, 2026 | msn.comMicrobot Medical Successfully Transitions to Commercial Operations as It Records Revenue Resulting from Its Limited Market Release During the First Quarter of 2026May 14, 2026 | globenewswire.comMicrobot Medical Inc. (MBOT) Reports Q1 Loss, Misses Revenue EstimatesMay 13, 2026 | zacks.comMicrobot Medical (MBOT) to Release Quarterly Earnings on WednesdayMay 6, 2026 | marketbeat.comMicrobot Medical®’s LIBERTY® Endovascular Robotic System is Now Adopted by Multiple Accounts Across Key Territories Including Two ACCESS-PVI Pivotal Clinical Trial SitesMay 5, 2026 | markets.businessinsider.comMicrobot Medical®'s LIBERTY® Endovascular Robotic System is Now Adopted by Multiple Accounts Across Key Territories Including Two ACCESS-PVI Pivotal Clinical Trial SitesMay 5, 2026 | globenewswire.comMicrobot Medical (NASDAQ:MBOT) Cut to "Strong Sell" at Wall Street ZenMay 2, 2026 | marketbeat.comMicrobot Medical® Announces the Addition of Senior Commercial Executive with Proven Track Record to Accelerate Commercial Readiness in Europe, the Middle East, and Asia (EMEA)April 30, 2026 | globenewswire.comStryker to Report Q1 Earnings: What's in Store for the Stock?April 28, 2026 | zacks.comMicrobot Medical Inc. (NASDAQ:MBOT) Receives Consensus Recommendation of "Moderate Buy" from AnalystsApril 26, 2026 | marketbeat.comMicrobot Medical® Welcomes Updated Occupational Protection Guidelines from Leading Medical Societies, Strengthening Commercial Position of LIBERTY®April 22, 2026 | globenewswire.comMicrobot Medical Begins Full U.S. Launch of LIBERTY SystemApril 15, 2026 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMBOT, KIDS, BBNX, and DCTH Company DescriptionsBeta Bionics NASDAQ:BBNX$10.60 +0.49 (+4.81%) As of 03:50 PM Eastern This is a fair market value price provided by Massive. Learn more.Beta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.Delcath Systems NASDAQ:DCTH$11.42 +0.20 (+1.74%) As of 03:50 PM Eastern This is a fair market value price provided by Massive. Learn more.Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.OrthoPediatrics NASDAQ:KIDS$18.43 -0.07 (-0.35%) As of 03:50 PM Eastern This is a fair market value price provided by Massive. Learn more.OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE Spine, BandLoc, Pediguard, Pediatric Nailing Platform | Femur, Devise Rail, Orthex, The Fassier-Duval Telescopic Intramedullary System, SLIMTM Nail, The GAP Nail, The Free Gliding SCFE Screw System, GIROTM Growth Modulation System, PNP Tibia System, ApiFix Mid-C System, and Mitchell Ponseti. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.Microbot Medical NASDAQ:MBOT$1.76 +0.03 (+1.44%) As of 03:50 PM Eastern This is a fair market value price provided by Massive. Learn more.Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending Target Shows Strengths, But Analysts Want to See More Freight Boom: The Hormuz Blockade Payday TJX Companies Fires on All Cylinders With 9% Revenue Growth Analog Devices Provides Much-Needed Pullback: How Low Can It Go? USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms From Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
